4-Methyl-4-[2-[2-methyl-4-(methylamino)butan-2-yl]oxyethoxy]pentan-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Methyl-4-[2-[2-methyl-4-(methylamino)butan-2-yl]oxyethoxy]pentan-2-one
• 英文别名: 4-methyl-4-[2-[2-methyl-4-(methylamino)butan-2-yl]oxyethoxy]pentan-2-one
• 化学式: C₁₄H₂₉NO₃
• 分子量: 259.38
• InChiKey: MSBPDIHBFXEGLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
  申请人：Genzyme Corporation

  公开号：US20140294867A1

  公开（公告）日：2014-10-02

  The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

  本公开提供了结合多肽（例如抗体）及其效应物基团共轭物（例如抗体药物共轭物或ADCs），其中包括结合多肽的天然或工程糖醛中的位点特异性设计的药物-糖醛连接。本公开还提供了编码抗原结合多肽的核酸、重组表达载体和宿主细胞，用于制备这种抗原结合多肽。还提供了使用本文所披露的抗原结合多肽治疗疾病的方法。
• US20140271676A1
  申请人：——

  公开号：US20140271676A1

  公开（公告）日：2014-09-18
• HYPERGLYCOSYLATED BINDING POLYPEPTIDES
  申请人：Genzyme Corporation

  公开号：US20150079070A1

  公开（公告）日：2015-03-19

  Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• GLYCOENGINEERED ANTIBODY DRUG CONJUGATES
  申请人：Genzyme Corporation

  公开号：US20160136299A1

  公开（公告）日：2016-05-19

  The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION
  申请人：Genzyme Corporation

  公开号：US20170107276A9

  公开（公告）日：2017-04-20

  Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.